Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abeona TherapeuticsABEO +0.90%30 Cash-to-Debt is 7.39 as of Jun. 2026, which is 21% below its 10-year median of 9.41. GuruFocus rates ABEO with a GF Score™ of 30/100. The stock has 5 warning signs investors should review. Among 1,393 Biotechnology companies, Abeona Therapeutics ranks better than 50.61% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Abeona Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 7.39.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Abeona Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Abeona Therapeutics's Cash-to-Debt or its related term are showing as below:
ABEO'
s Cash-to-Debt Range Over the Past 10 Years
Min: 2.19 Med: 9.41 Max: No Debt
Current: 7.39
During the past 13 years, Abeona Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 2.19. And the median was 9.41.
ABEO's Cash-to-Debt is ranked better than 50.61% of 1393
companies
in the Biotechnology industry
Industry Median: 7.03
vs ABEO: 7.39
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Abeona Therapeutics Cash-to-Debt Related Terms
Abeona Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Abeona Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Abeona Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abeona Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Abeona Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abeona Therapeutics (ABEO) has a Cash-to-Debt of 7.39 as of Jun. 2026. This is 21% below median its historical median of 9.41. Over the past decade, Abeona Therapeutics' Cash-to-Debt has ranged from 2.19 to 10,000.00. According to the industry distribution chart, Abeona Therapeutics ranks #688 out of 1393 companies in the Biotechnology industry, placing it in the top 49.4%.
Is Abeona Therapeutics' Cash-to-Debt too high?
Abeona Therapeutics' current Cash-to-Debt of 7.39 is 21% below median its 10-year median of 9.41. Over the past 10 years, this metric has ranged from a low of 2.19 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.03. Abeona Therapeutics' value of 7.39 is 5.1% above this industry median. Based on the distribution chart, Abeona Therapeutics ranks #688 out of 1393 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Abeona Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' Cash-to-Debt compare to STRO and IKT?
According to the Biotechnology industry distribution chart, Abeona Therapeutics ranks #688 out of 1393 companies for Cash-to-Debt. This puts Abeona Therapeutics in the upper half of its industry. The industry median Cash-to-Debt is 7.03. Abeona Therapeutics' value of 7.39 is 5.1% above this benchmark. Historically, Abeona Therapeutics' own Cash-to-Debt has ranged from 2.19 to 10,000.00 over the past decade. While the company's 10-year median is 9.41 vs. the industry median of 7.03, Abeona Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abeona Therapeutics's current Cash-to-Debt of 7.39 is 5.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abeona Therapeutics's current Cash-to-Debt is 7.39, which is 21% below median its own 10-year median of 9.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Abeona Therapeutics (ABEO) has a current Cash-to-Debt of 7.39. The current Cash-to-Debt is 7.39, which is 21% below median its 10-year median of 9.41 and 5.1% above the Biotechnology industry median of 7.03. Abeona Therapeutics' overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Abeona Therapeutics (ABEO), the current Cash-to-Debt is 7.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
30GF Score
Get the complete analysis for ABEO
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABEO has been successfully added to your 
